SAILIFE

Sai Life Sciences Financial Results

₹1,566.00+0.51%
Market cap
₹33,165 crore
P/E
91.7
P/B
13.35
ROE
15.1%
Dividend yield
1.20%

For the year ended Mar 2023, Sai Life Sciences reported revenue of ₹1,197 crore and net profit of ₹10 crore, against ₹1,456 crore and ₹83 crore a year earlier.

Sai Life Sciences annual profit and loss

Financial years, newest first. TTM = trailing twelve months.

Sai Life Sciences annual profit and loss (₹ crore)
ItemMar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue1,1971,4561,6602,1372,195
Expenses1,0211,1561,2491,5031,533
Operating profit176301412634661
Operating margin %15%21%25%30%30%
Other income1714313832
Interest7786763935
Depreciation99119139167175
Profit before tax16109228466483
Tax %39%24%25%25%25%
Net profit1083170349362
EPS (₹)0.483.988.1616.4817.08
Dividend payout %—————

Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.

Sai Life Sciences financial results — frequently asked questions

What is Sai Life Sciences' annual revenue and net profit?

For the financial year ended Mar 2023, Sai Life Sciences' revenue was ₹1,197 crore and net profit ₹10 crore; net profit fell 87.95% from ₹83 crore in Mar 2024.

How fast has Sai Life Sciences grown over three years?

From Mar 2026 to Mar 2023, Sai Life Sciences' revenue grew at a compound annual rate of -17.6% and net profit at -69.4%. Past growth does not indicate future results.

What is the EPS of Sai Life Sciences?

Annual EPS for Mar 2023 was ₹0.48.

Are these figures consolidated or standalone?

They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.

Same Data For Peers

Trade Sai Life Sciences With ATS

Track SAILIFE live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.